Related Experiment Video
Updated: May 26, 2025
06:41
A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis
Published on: March 9, 2015
8.9K
Pediatric Ewing's Sarcoma and Permanent Chemotherapy-Induced Alopecia: A Case-Control Study.
Madeline Lillich1, Stuart Gold2, Diana McShane3
1School of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.
Pediatric Dermatology
|February 23, 2025
Summary
Permanent chemotherapy-induced alopecia (PCIA) is a rare condition in pediatric cancer survivors. This study found PCIA can occur after Ewing
Area of Science:
- Pediatric Oncology
- Dermatology
- Oncology
Background:
- Permanent chemotherapy-induced alopecia (PCIA) is defined as persistent hair loss >6 months after chemotherapy.
- PCIA is a rare diagnosis, particularly in pediatric patients.
- Ewing's sarcoma (ES) treatment involves intensive chemotherapy regimens.
Purpose of the Study:
- To characterize PCIA in pediatric patients treated for Ewing's sarcoma (ES).
- To identify potential risk factors and treatment outcomes for PCIA in this population.
Main Methods:
- Retrospective chart review of pediatric ES patients.
- Comparison of demographic factors, chemotherapy dosing, and family history between PCIA cases and controls.
- Evaluation of treatment interventions for PCIA.
Main Results:
- Three out of 12 pediatric ES patients reviewed were diagnosed with PCIA.
- Demographic factors, cumulative dosing, and family history were analyzed.
- Topical and oral minoxidil showed some benefit but did not guarantee complete hair regrowth.
Conclusions:
- PCIA can occur in pediatric patients following treatment for Ewing's sarcoma.
- Minoxidil may offer partial benefit for PCIA, but complete regrowth is not assured.
- Further research is needed to understand and manage PCIA in pediatric cancer survivors.
